Últimas noticias sobre FuboTV (NYSE:FUBO) Bolsa

FUBOTV INC

FuboTV

FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.

Brazil,,Rio,De,Janeiro,-,May,19,,2023:,In,This

Long Ideas

News

Markets

Media

Trading Ideas

ATEX

CABO

FUBO

3 acciones del sector de servicios de comunicación presentan niveles de RSI por debajo de 30, lo que sugiere oportunidades de inversión.

Acciones sobrevendidas en comunicación revelan oportunidades: FuboTV, Cable One y Anterix

Equities

Market Summary

Futures

Economics

Federal Reserve

Pre-Market Outlook

Analyst Ratings

BHAT

CALM

NVDA

TSLA

XTIA

Los futuros de EE.UU. avanzan antes del cierre del jueves. Descubre qué sectores lideran y qué esperar esta semana.

Los futuros de EE.UU. suben: ¿Qué esperar del mercado antes del cierre del jueves?

Eurozone

Commodities

Intraday Update

AEON

BLRX

SPRC

Los mercados financieros avanzan con el Dow Jones subiendo 200 puntos. Conoce las acciones ganadoras, caídas y tendencias en materias primas.

Índices bursátiles al alza: Las acciones tecnológicas impulsan a Wall Street este lunes

FuboTV Inc

FUBON FINCL HLDG CO ORD by Fubon Financial Holding Co. Ltd.

Fubon Financial Holdings Co Ltd

FUBON FINCL HL S/GDR 144A by Fubon Financial Holding Co. Ltd.

FUBON FINCL HLD S/GDR by Fubon Financial Holding Co. Ltd.

Maxim Group analyst Michael Okunewitch maintains HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) with a Buy and lowers the price target from $120 to $35.

Price Target

HCWB

Maxim Group Maintains Buy on HCW Biologics, Lowers Price Target to $35

Guidance

Rumors

Watching United Airlines; CEO Reportedly Says Co Took A Big Drop In Leisure Demand Bookings Over Past Months; Drop In Load Factor Will Impact Bottom Line

Shares of Salesforce Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) tanked in early trading on Thursday, despite the company Wednesday reporting <a href="https://www.benzinga.com/news/earnings/25/05/45657851/salesforce-q1-earnings-revenue-beat-eps-beat-raised-guidance-momentum-in-agentic-ai-shares-surge">strong first-quarter results</a>.
Here are some key analyst takeaways.
<ul class="wp-block-list">
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58c6ab8db85e9300015f1ae0/kash-rangan">analyst Kash Rangan</a> reaffirmed a Buy rating, while lifting the price target from $340 to $385.</li>
<li>Needham <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587635595064ed000140010c/scott-berg">analyst Scott Berg</a> maintained a Buy rating and price target of $400.</li>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d5296ab85e930001416e5a/mark-murphy">analyst Mark Murphy</a> reiterated an Overweight rating and price target of $380.</li>
<li>Bank of America Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59ca95686ab12400018386cb/brad-sillshttps:/www.benzinga.com/analyst-stock-ratings/analyst/59ca95686ab12400018386cb/brad-sills">analyst Brad Sills</a> reaffirmed a Buy rating and price target of $350.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Goldman Sachs: Salesforce's reported solid quarterly results and raised its full-year revenue guidance, Rangan said in a note. Shares came under pressure due to margin concerns, he added.
Salesforce's margins have typically expanded amid tough demand environments and contracted back as the macro improves, the analyst stated. While the company's margins have expanded, this trend may continue instead of reversing, given "management's strong emphasis on profitable growth at scale today," even when the macro recovery begins, he further wrote.
Needham: Salesforce reported revenues and earnings of $9.83 billion and $2.58 per share, Berg said. Total revenues grew 7.6% year-on-year, driven by 8.3% subscription revenue, with "strength in Data / AI oriented clouds and products along with pricing and packaging in sales and service," he added.
Data Cloud and AI annual recurring revenue crossed $1 billion, up more than 120%, the analyst stated. "cRPO (current remaining performance obligation), our favorite sales metric, grew 12.1% Y/Y (11% in CC) versus 10% guidance," he further wrote.
JPMorgan: Salesforce's cRPO grew 11% to $29.6 billion, flat versus the previous quarter, Murphy said. However, the second-quarter cRPO growth guidance came in around 30bps below Street expectations, he added.
The company delivered an "uncharacteristic" miss on operating margins, the analyst stated. Total revenue of $9.83 billion, up 8% in constant currency terms, surpassed consensus, "driven by 9% growth in Subscription &amp; Support revenue," he further wrote.
BofA Securities: Salesforce's first-quarter results suggest "a stable demand environment, with continued strength in the Agentforce new product cycle," Sills wrote in a note.
Management reiterated their outlook for subscription growth of 9% in constant currency terms for fiscal 2026, which was "a welcome relief," given that channel checks suggested a guide down, the analyst stated. The timing of growth acceleration remains unclear, he added.
Price Action: Shares of Salesforcehad declined by 5.85% to $259.89 at the time of publication on Thursday.
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45663035/salesforce-declares-multitrillion-dollar-opportunity-with-digital-labor-revolution-jim-cramer-says-crm-is-doing-exciting-things">Salesforce Declares &#8216;Multitrillion Dollar Opportunity&#8217; With Digital Labor Revolution: Jim Cramer Says CRM Is Doing &#8216;Exciting Things&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings Beats

Reiteration

Movers

Salesforce Posts Q1 Beat As AI Crosses $1B, But How Concerned Should Investors Be About Margins?

Loop Capital analyst Rob Sanderson maintains Sea (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) with a Buy and raises the price target from $165 to $190.

Loop Capital Maintains Buy on Sea, Raises Price Target to $190

<a href="https://nuvve-crypto.com/" title="https://nuvve-crypto.com/">https://nuvve-crypto.com/</a>

NVVE

Watching Nuvve Holding; Shares See A Spike In Volume, Traders Circulate Domain Name "Nuvve-Crypto.com"

HP Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>) reported weaker-than-expected earnings for the second <a href="https://www.benzinga.com/quote/HPQ/earnings">quarter on Wednesday</a>.
HP reported second-quarter revenue of $13.22 billion, beating analyst estimates of $13.15 billion. The company reported second-quarter adjusted earnings of 71 cents per share, missing estimates of 80 cents per share, according to Benzinga Pro.
"In Q2, we delivered solid revenue growth, led by strong Commercial performance in Personal Systems and continued momentum behind our future of work strategy," said Enrique Lores, president and CEO of HP.
HP said it expects third-quarter adjusted earnings of 68 cents to 80 cents per share versus estimates of 90 cents per share. The company also lowered its full-year adjusted earnings outlook from a range of $3.45 to $3.75 per share to a new range of $3 to $3.30 per share. Analysts had been anticipating full-year adjusted earnings of $3.49 per share.
HP shares fell 6.4% to trade at $25.42 on Thursday.
These analysts made changes to their price targets on HP following earnings announcement.
<ul class="wp-block-list">
<li>JP Morgan analyst Samik Chatterjee maintained HP with an Overweight rating and lowered the price target from $30 to $27.</li>
<li>Barclays analyst Tim Long maintained HP with an Equal-Weight rating and cut the price target from $36 to $28.</li>
</ul>
Considering buying HPQ stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="580" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29113043/image-393-1024x580.png" alt="" class="wp-image-931827" style="width:681px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29113043/image-393-1024x580.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29113043/image-393-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29113043/image-393-768x435.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29113043/image-393.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45641430/jim-cramer-says-this-quantum-computing-stock-is-so-high-and-too-speculative">Jim Cramer Says This Quantum Computing Stock Is &#8216;So High&#8217; And &#8216;Too Speculative&#8217;</a> </li>
</ul>
Photo via Shutterstock

Earnings

These Analysts Slash Their Forecasts On HP Following Downbeat Earnings

Barclays analyst Lauren Lieberman maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Equal-Weight and raises the price target from $56 to $63.

Barclays Maintains Equal-Weight on Estee Lauder Cos, Raises Price Target to $63

Fiserv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>) has outperformed the market over the past 20 years by 6.09% on an annualized basis producing an average annual return of 14.37%. Currently, Fiserv has a market capitalization of $89.95 billion. 
Buying $1000 In FI: If an investor had bought $1000 of FI stock 20 years ago, it would be worth $14,488.73 today based on a price of $162.23 for FI at the time of writing.
<h3>Fiserv's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748532613_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Tempus AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) just got hit with a short seller grenade—and <a href="https://www.benzinga.com/25/05/45660989/cathie-wood-ditches-5-6m-more-tesla-while-elon-musk-quits-government-role-doubles-down-on-ai-stock-under-attack-by-short-sellers">Cathie Wood showed up with a shopping cart</a>.
Shares of the precision medicine player plunged over 19% on Wednesday after Spruce Point Capital launched <a href="https://www.benzinga.com/25/05/45648906/tempus-ai-stock-sinks-after-short-seller-flags-ceo-track-record-suspicious-accounting-50-downside-potential">a scathing report</a> targeting the company's credibility and AI prowess. 
But while the Street panicked, Wood's ARK ETFs swooped in, grabbing 251,080 shares worth over $16.5 million. Clearly, she sees blood in the streets—and potential on the charts.
Read Also: <a href="https://www.benzinga.com/25/05/45661519/nvidia-apple-amazon-tempus-ai-tesla-why-these-5-stocks-are-on-investors-radars-today">Nvidia, Apple, Amazon, Tempus AI, Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0529"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29094906/Screenshot-2025-05-29-at-4.54.18-PM.png" alt="" class="wp-image-931645" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29094906/Screenshot-2025-05-29-at-4.54.18-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29094906/Screenshot-2025-05-29-at-4.54.18-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0529" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">Golden Cross Meets Golden Opportunity</h2>
Amid the chaos, Tempus quietly flashed a bullish technical indicator: a Golden Cross. That's when the 50-day simple moving average crosses above the 200-day simple moving average—a classic sign that the long-term trend is strengthening.
Despite the short-term carnage, the stock still trades above both the 50-day and 200-day simple moving averages—at $55, compared to $52.61 and $52.18, respectively. That's a bullish signal. The Moving Average Convergence Divergence (MACD) indicator sits at 1.76, adding to the bullish case. Even the Relative Strength Index (RSI) reads 47.07, skirting just under neutral territory—suggesting the stock isn't overbought or oversold.
<h2 class="wp-block-heading">Bears In Control For Now</h2>
That said, the near-term trend remains shaky. With the stock trading below its eight-day, and 20-day simple moving averages, there's clear selling pressure. Technically, that flags a bearish trend in the short term, despite the promising long-term crossover.
But that's precisely the setup Wood seems to love: a company with long-term vision, currently misunderstood by the market—and cheap.
<h2 class="wp-block-heading">Betting On Data, Not Doubt</h2>
Tempus AI has yet to turn a profit, but it's building something substantial. It supported nearly 1,500 research projects over the past decade and reported a <a href="https://www.benzinga.com/quote/TEM/earnings">solid revenue beat</a> in the first quarter. Critics can debate the AI capabilities, but the company's reach in precision medicine is real.
If Wood is right, this pullback may go down as a textbook shakeout—and the Golden Cross, a signal of what's to come.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45664231/teslas-optimus-may-be-the-first-humanoid-robot-to-achieve-high-volume-and-tech-scale-says-nvidia-ceo-jensen-huang-likely-to-be-the-next-multi-trillion-dollar-industry">Tesla&#8217;s Optimus May Be The First Humanoid Robot To Achieve High Volume And Tech Scale, Says Nvidia CEO Jensen Huang: &#8216;&#8230; Likely To Be The Next Multi-Trillion Dollar Industry&#8217;</a></li>
</ul>
Photo: Shutterstock

Short Sellers

Technicals

Tech

Tempus: Short Seller Attack Brings Golden Opportunity Cathie Wood Was Waiting For

Intellia Therapeutics Inc (NASDAQ: NTLA) said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Phase 3 MAGNITUDE study.
The trial is evaluating nexiguran ziclumeran (nex-z, also known as NTLA-2001) in transthyretin amyloidosis <a target="_blank" href="https://www.intelliatx.com/pipeline/clinical-trials/" rel="noreferrer noopener">with</a> cardiomyopathy.
These elevations appear to be resolving&nbsp;without hospitalization or medical intervention&nbsp;and have fallen to grade 3 ALT and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">grade 2 AST elevations</a>.
The company has enrolled approximately 365 patients in the MAGNITUDE study out of an expected total enrollment of approximately 765.
The company expects to complete enrollment by early 2027.&nbsp;Over 200 patients have been dosed with nex-z in the MAGNITUDE study.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42923296/why-is-intellia-therapeutics-stock-trading-lower-on-friday" rel="noreferrer noopener">Why Is Intellia Therapeutics Stock Trading Lower On Friday?</a>
In an SEC filing, the company reported that adverse events have been similar to those reported in the Phase 1 study of Nex-z for ATTR amyloidosis and have included infusion-related reactions and asymptomatic liver transaminase elevations.
William Blair writes, &#8220;We remain positive on the risk/benefit given the two reported grade 4 LFT (liver function test) events with nex-z have been asymptomatic to date, avoided hospitalization, and are likely to resolve without medication, in our view.&#8221;
The regulatory filing <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001652130/000119312525129524/d40487d8k.htm" rel="noreferrer noopener">states</a> that enrollment in the global&nbsp;Phase 3 HAELO study of NTLA-2002 for hereditary angioedema is on track.&nbsp;
The company expects to complete enrollment in the third quarter of 2025 and submit a biologics license application (BLA) in the second half of 2026 to support plans for a potential U.S. commercial launch in 2027.
Enrollment in the global Phase 3 MAGNITUDE-2 study of nex-z for ATTRv-PN is also progressing well. The study is designed to measure clinical outcomes and evaluate how a single dose of Nex-z can reduce serum TTR.
Intellia expects to complete MAGNITUDE-2 by 2028 to support a potential BLA submission and a potential U.S. commercial launch in 2029.
HC Wainwright reiterated Intellia Therapeutics with a Buy and maintains a $30 price target.
Price Action: At the last check on Thursday, NTLA stock was down 22.6% at $7.48 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45655797/boston-scientific-scraps-this-aortic-valve-sticks-to-2025-outlook" target="_blank" rel="noreferrer noopener">Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

General

NTLA

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

Barclays analyst Saket Kalia maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Overweight and raises the price target from $285 to $300.

VEEV

Barclays Maintains Overweight on Veeva Systems, Raises Price Target to $300

WTGUU

Trading Halt: Halt status updated at 11:25:00 AM ET: Quotation Resumption: IPO Security - Released for Quotation

Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Thursday.</a>
The company reported first-quarter adjusted earnings per share of $1.60, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45665089/burlington-stores-inc-reports-first-quarter-2025-earnings" rel="noreferrer noopener">analyst consensus estimate of $1.41</a>. Quarterly sales of $2.50 billion missed the Street view of $2.52 billion.
Total sales&nbsp;increased 6% year over year, while comparable store sales were flat.
&#8220;We anticipate that tariffs will put significant pressure on our merchandise margin, but we are confident that, as long as tariffs do not increase from current levels, we can offset this pressure elsewhere in the P&amp;L,&#8221; said the company&#8217;s CEO Michael O&#8217;Sullivan.
Also Read: <a target="_blank" href="http://benzinga.com/etfs/sector-etfs/25/05/45553623/retail-etfs-rattle-as-tariffs-yields-consumer-caution-pressure-big-box-stocks" rel="noreferrer noopener">Retail ETFs Rattle As Tariffs, Yields, Consumer Caution Pressure Big-Box Stocks</a>
Gross margin&nbsp;in the quarter under review expanded to 43.8% from 43.5%, an increase of 30 basis points year over year. Merchandise margin expanded 20 basis points.
Adjusted EBITDA&nbsp;was $244 million compared with $217 million in the first quarter of fiscal 2024, excluding $6 million of expenses in each period associated with bankruptcy-acquired leases.
Merchandise inventories soared 15% on a year-over-year basis to $1.315 billion. Comparable store inventories decreased 8%.
The company exited the quarter with cash and equivalents worth $371.092 million, and long-term debt of $1.637 billion.
Outlook: Burlington Stores sees second-quarter adjusted EPS of $1.20-$1.30 versus the $1.34 estimate. The firm expects total sales to increase in the range of 5% to 7%; this assumes comparable store sales will increase in the range of 0% to 2%.
For FY25, the firm expects total sales to increase in the range of 6% to 8% on top of the 11% increase during Fiscal 2024.
The company projects the firm to open approximately 100 net new stores.
Burlington Stores reiterated its FY25 Adj EPS guidance of $8.70-$9.30 versus the $9.24 estimate.
Price Action: BURL shares are trading higher by 2.39% to $245.08 at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/content/45654771/2-red-hot-stocks-with-high-rsis-and-more-upside-to-come" target="_blank" rel="noreferrer noopener">2 Red-Hot Stocks With High RSIs and More Upside to Come</a></li>
</ul>
Image: Shutterstock

BURL

Burlington Beats Q1 Earnings, CEO Vows To Absorb Tariff Heat Through Gains Elsewhere

Real estate markets are still not getting a lot of love from the investing world. Even though sales and pricing have been increasing, there is still fear of what may happen if the bond market does not get its act under control. The price of real estate and REITs are very closely correlated to the yield of ten-year treasuries, and that is a concern.
I am comfortably in the camp of &#8220;Stagflation is inevitable&#8221; thanks to the current trade policy and high levels of uncertainty. However, I am not in the camp of &#8220;The end is nigh.&#8221;
Given the nasty bear market we have experienced and the levels of fear in the marketplace, it is quite likely that we are closer to a bottom than the markets want to accept. Even those who are bullish on the economy and the markets tend to overlook real estate.
Even though real estate has created more millionaires and even billionaires than any other asset class, there is a perception that owning REITs is boring. While REITs have languished in the past few years, it was hard to be comfortable with calling a bottom as we did not see insiders step up to the plate as they have at previous bottoms in the REIT market. That is starting to change. In recent weeks, buying activity by the officers and directors of real estate investment trusts has been picking up.
Americold Realty Trust (Ticker: COLD)
One of the largest rounds of insider buying recently was at Americold Realty Trust (COLD). Everything you buy requires storage at some point in its journey from the manufacturer to you. A lot of the things you buy, especially at the grocery store, require that storage facility to be temperature controlled—specifically, controlled to be cold.
Americold owns 238 cold storage facilities around the world. Its customers include some of the largest food producers and grocery chains in the world. Here in the United States, their locations cover 99% of the population.
There are key megatrends helping drive the demand for cold storage:
<ul class="wp-block-list">
<li>We are trying to eat healthier, which requires fresh food</li>
<li>Meal kits have seen a meteoric rise in popularity, and most of them have to be refrigerated at every step of the supply chain</li>
</ul>
Americold has seen revenues rise by 60% over the past five years, and net operating income has grown by 69%. The stock has fallen by more than 50% from its pandemic highs, and insiders are starting to buy shares in anticipation of a massive long-term rebound.
CEO George Chapelle bought $1.9 million worth of stock earlier this month. CFO Jay Wells spent $179,000 to add to his position in the REIT. Americold just raised the dividend by 5%, and the shares now yield about 5.5%.
BRT Apartments Corp. (Ticker: BRT)
It seems that every time there is even a hint of a lull in the real estate markets, Jeffrey Gould increases his stake in BRT Apartments (BRT). I bought BRT shares years ago when they made the transition from a mortgage REIT to an owner of apartments. It was insider buying that drew my attention to the stock, and we are still seeing strong buying today.
Gould has been in the real estate investment game for a long time and is also a director at One Liberty Properties (OLP), a net lease REIT.
BRT Apartments Corp. is a small-cap multifamily REIT focused on garden-style and mid-rise apartment communities across the Southeast and Texas. The company operates a portfolio of 29 properties with nearly 8,000 units. At the current price, the shares yield 6.29%. The REIT is also actively buying back stock to take advantage of the favorable valuation right now.
The Gould family owns about 40% of the REIT, but Jeffrey Gould just keeps buying. Notably, in May 2025, he purchased 25,238 shares valued at approximately $385,134. Earlier, in April 2024, Gould acquired shares worth over $625,000.
Pebblebrook Hotel Trust (Ticker: PEB)
Hotel REITs have underperformed all year, and the decline is starting to create the kind of bargain pricing that attracts insiders. Pebblebrook Hotels (PEB) Chairman and CEO Jon Bortz has been aggressively buying shares since March. His most recent purchases were in May when he purchased about $1.5 million in additional shares of the REIT.
Pebblebrook Hotel Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEB#NYSE">PEB</a>) is a lodging-focused REIT that owns a portfolio of upper-upscale, full-service hotels and resorts concentrated in high-barrier, urban and resort markets across the United States. Pebblebrook has carved out a niche investing in lifestyle-oriented properties in gateway cities like San Francisco, Washington D.C., Boston, and Key West. The portfolio includes over 50 hotels and resorts, featuring well-known properties like 1 Hotel San Francisco, Hotel Zena in D.C., and the Southernmost Beach Resort in Key West.
Real estate is out of favor with investors, but insiders are slowly but surely stepping up to the plate.

Opinion

COLD

Alpha Buying: Real Estate May Be Cold, but Insider Confidence Is Heating Up

WIIM

HUSA

Houston American Energy shares are trading lower after the company announced a 1-for-10 reverse stock split.

After graduating and landing a professional marketing role in New York City, one Reddit user thought they were off to a strong start. But after receiving their first paycheck, reality hit hard: nearly 80% of their take-home pay <a href="https://www.benzinga.com/markets/25/05/45573478/new-york-citys-housing-market-is-so-tough-that-its-now-the-second-most-expensive-city-in-the-world-i">went to rent</a>.
&#8220;After taxes, utilities, student loans, and transportation, there&#8217;s barely anything left for food, let alone saving or any semblance of a social life,&#8221; the person wrote in the <a href="https://www.reddit.com/r/jobs/comments/1kw5xnr/just_started_my_professional_job_and_realized_my/">r/jobs</a> subreddit recently.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">Roommates Are The Reality</h2>
The original poster said they weren&#8217;t expecting the shock: &#8220;I feel like I&#8217;m playing a game where the rules changed, but no one told me.&#8221;
The overwhelming consensus in the replies was that living solo in a major city just isn&#8217;t doable for most new grads. &#8220;I <a href="https://www.benzinga.com/personal-finance/24/11/42193386/mark-cuban-shared-600-a-month-dallas-apartment-with-5-guys-and-slept-on-the-living-room-floor-i-had-nothing-so-i-had-nothing-to-lose">lived with roommates in a big city</a> for five years until I earned a six-figure paycheck,&#8221; one commenter said. &#8220;Very few people can afford to live on their own fresh out of the gate.&#8221;
Another added, &#8220;Everyone in big cities has roommates early in their careers or until they get married.&#8221; To them, it&#8217;s not weird or embarrassing.
Trending: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
Several people shared that communal living has always been the norm. &#8220;My grandmother, who was born in 1933, lived in a woman&#8217;s house when she moved to the city for work. She had her own bedroom, but she shared a bathroom, had a curfew, and part of her rental fee went to breakfast and dinner,&#8221; one person recalled.
Many said this has long been the case for young workers in big cities. One person called it out as a common mistake: &#8220;He rented accommodation. Then he accepted a job offer. And only then did he do the maths. He just realized it.&#8221;
<h2 class="wp-block-heading">Wider Economic Frustration</h2>
Some said the situation reflects broader economic problems. &#8220;The problem is that <a href="https://www.benzinga.com/personal-finance/24/12/42496912/warren-buffett-doesnt-believe-college-is-for-everyone-none-of-his-3-kids-finished-if-you-pool-their-credits-you-got-a-degree">the education system</a> lies,&#8221; one said. &#8220;They tell you that you cannot get anywhere in life without a 4-year bachelor's degree in something. [Then] you graduate, get a job, get a place, get bills rolling in and realize the hard way that you were sold a bunch of sh&#x2A;t.&#8221;
Others pointed to <a href="https://www.benzinga.com/etfs/sector-etfs/25/05/45330230/jobs-up-wages-down-financial-etfs-may-have-just-found-their-sweet-spot">wage stagnation</a> and <a href="https://www.benzinga.com/markets/25/02/43818622/buying-just-keeps-getting-more-expensive-study-shows-home-prices-up-in-89-of-us-cities-in-2024">inflated housing costs</a>: &#8220;I don&#8217;t know anyone who doesn't have at minimum two incomes coming into their home.&#8221;
See Also: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a>&nbsp;
<h2 class="wp-block-heading">What Now?</h2>
Advice ranged from practical to hard truths. &#8220;Either your rent is too high and you need to move, or your pay is too low and you need to get a higher-paying job,&#8221; one person wrote. Another chimed in: &#8220;It&#8217;s more likely both.&#8221;
The message was obvious: get roommates, cut expenses, or reconsider the job. Some suggested side gigs or moving farther out from the city. Others encouraged using the current job as a stepping stone to better opportunities.
&#8220;You aren&#8217;t supposed to &#8216;make it&#8217; right out the gate,&#8221; one commenter said. &#8220;Many are living with roommates, living in sub-optimal apartments. If you're living the &#8216;good life&#8217; in a modern apartment with an entry-level job, that's the trade-off you're making.&#8221;
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

'Rules Changed, But No One Told Me'—A Young Professional Says Their Rent Is 80% Of Take-Home Pay. How Is This Supposed To Be Sustainable?

ORIC Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORIC#NASDAQ">ORIC</a>) released preliminary efficacy and safety data on Wednesday from its ongoing Phase 1b trial of once daily ORIC-944 in combination with androgen receptor (AR) inhibitors in patients with metastatic castration-resistant <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">prostate cancer (mCRPC)</a>.
Preliminary activity analysis:
<ul class="wp-block-list">
<li>59% of patients (10/17) achieved a PSA50 response and nearly all patients with a PSA50 response were confirmed one month later, for a confirmed PSA50 response rate of 47% (8/17), which does not include one additional PSA <a href="https://www.benzinga.com/pressreleases/25/05/g45656385/oric-pharmaceuticals-announces-potentially-best-in-class-preliminary-efficacy-and-safety-data-from" target="_blank" rel="noreferrer noopener">response pending confirmation</a>.</li>
<li>24% of patients (4/17) achieved a PSA90 response, all of which were subsequently confirmed.</li>
<li>PSA responses were observed across all ORIC-944 dose levels and at comparable rates in combination with apalutamide or darolutamide.</li>
<li>The majority of patients are still ongoing, with multiple patients approaching one year or more on therapy. Further dose exploration is ongoing.</li>
</ul>
Preliminary safety analysis:
<ul class="wp-block-list">
<li>ORIC-944 combined with apalutamide or with darolutamide has been generally well tolerated to date. The majority of adverse events (AEs) are Grade 1 or 2 in severity and consistent with PRC2 and AR inhibition.</li>
</ul>
Following completion of the Phase 1b dose exploration portion of the trial expected in mid-2025, the company plans to evaluate two candidate RP2Ds for each combination in the dose optimization portion of the trial in 2H 2025.
Data from the dose optimization portion of the trial will inform the choice of ORIC-944 dose to advance in combination with apalutamide or with darolutamide in the company&#8217;s first global Phase 3 registrational trial in mCRPC, which it expects to initiate in 1H 2026.
The company announced a concurrent $125 million private placement financing that it expects will extend the cash runway into the second half of 2027 and through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 registrational trial in mCRPC.
<ul class="wp-block-list">
<li>The company will sell approximately 19.2 million shares in a private placement at $6.50 per share (or $6.4999 per <a href="https://www.benzinga.com/pressreleases/25/05/g45656386/oric-pharmaceuticals-announces-125-million-private-placement-financing" target="_blank" rel="noreferrer noopener">pre-funded warrant)</a>.&nbsp;</li>
</ul>
Price Action: At the last check on Thursday, ORIC stock was up 24.7% at $7.44 during the premarket session.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45664619/shell-boosts-nigerian-deepwater-assets-with-totalenergies-stake-purchase" target="_blank" rel="noreferrer noopener">Shell Boosts Nigerian Deepwater Assets With TotalEnergies Stake Purchase</a></li>
</ul>
Photo: Shutterstock

Financing

Offerings

ORIC

ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital

AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) has outperformed the market over the past 5 years by 6.06% on an annualized basis producing an average annual return of 19.97%. Currently, AECOM has a market capitalization of $14.31 billion. 
Buying $1000 In ACM: If an investor had bought $1000 of ACM stock 5 years ago, it would be worth $2,755.42 today based on a price of $108.15 for ACM at the time of writing.
<h3>AECOM's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748531729_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In AECOM 5 Years Ago Would Be Worth This Much Today

Intensity Therapeutics, Inc. (&quot;Intensity&quot;&nbsp;or &quot;the Company&quot;) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces that the Company will be presenting a Trials in Progress poster outlining its <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4436350-1&amp;h=1972245731&amp;u=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT06263231%3Fterm%3DINT230-6%26rank%3D3&amp;a=Phase+3+INVINCIBLE-3">Phase 3 INVINCIBLE-3</a> clinical trial of INT230-6 for the treatment of metastatic soft tissue sarcomas. The poster will be shown at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting held at McCormick Place in Chicago May 30-June 5, 2025.
The poster, titled, &quot;A Multicenter, Randomized, Global Phase 3 Study to Assess the Efficacy and Safety of Intratumoral (IT) INT230-6 (SHAO, VINblastine, Cisplatin) as Monotherapy Compared with Standard of Care Systemic Chemotherapy in Adults with Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (STS) (INVINCIBLE-3),&quot; will be presented by Sant P. Chawla M.D., Director, Sarcoma Oncology Center of Southern California, during the &quot;Sarcoma&quot; session to be held on Saturday May 31, 2025 from 9:30 AM to 12 PM on panel 66a. An abstract of the poster, which outlines the Company&#39;s Phase 3 study protocol, can be found <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4436350-1&amp;h=875344405&amp;u=https%3A%2F%2Fwww.asco.org%2Fabstracts-presentations%2FABSTRACT503972&amp;a=here.">here.</a>

INTS

Reported Earlier: Intensity Therapeutics To Present Phase 3 INVINCIBLE-3 Trial Poster For INT230-6 In Metastatic Soft Tissue Sarcomas At ASCO 2025 Annual Meeting

Barclays analyst Kannan Venkateshwar maintains SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) with a Equal-Weight and lowers the price target from $21 to $19.

Barclays Maintains Equal-Weight on SentinelOne, Lowers Price Target to $19

Press Releases

Fubo Launches Multicultural Standalone and Add-on Content Bundles; Zee Family Is First New Offering

Fubo Expands Local Programming With Launch of CHCH TV

Fubo Closed 2024 With Record $1.59B Revenue, 1.676M Paid Subscribers in North America

Fubo to Stream Texas Rangers Baseball Through New Carriage, Sponsorship Agreement With Rangers Sports Network

Fubo to Announce Q1 2025 Financial Results on May 2, 2025

Fubo Announces Inducement Grants Under NYSE Listing Rule 303A.08

Fubo Retains Exclusive Rights to Premier League in Canada With Multi-Year Agreement Beginning With 2025/2026 Season

Fubo's Global Streaming Business Exceeded Subscriber Guidance, Achieved Revenue Targets in Q1 2025

Fubo Brings Live European League of Football to Fubo Sports Fast Network With Multi-Year Agreement

Fubo Launches First to Market Programmatic Pause Ads on CTV

Autohome Inc. American Depositary Shares, each representing four class A ordinary shares.

Comments

FuboTV

Noticias

Últimas noticias sobre FuboTV (NYSE:FUBO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL